Compare BAER & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAER | MREO |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.9M | 50.3M |
| IPO Year | 2023 | 2017 |
| Metric | BAER | MREO |
|---|---|---|
| Price | $0.79 | $0.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $5.00 | $1.50 |
| AVG Volume (30 Days) | 635.5K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.15 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $122,830,000.00 | $500,000.00 |
| Revenue This Year | $16.47 | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 24.56 | N/A |
| 52 Week Low | $0.83 | $0.20 |
| 52 Week High | $3.44 | $2.37 |
| Indicator | BAER | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 21.22 | 66.87 |
| Support Level | N/A | $0.31 |
| Resistance Level | $2.06 | $0.35 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 0.06 | 82.55 |
Bridger Aerospace Group Holdings Inc operates as an aerial firefighting company. It provides aerial wildfire surveillance, relief and suppression, and aerial firefighting services using next-generation technology and environmentally friendly and sustainable firefighting methods. Its revenues is derived from aerial wildfire management, relief and suppression and the delivery of specialty aviation services. The company's portfolio is organized across three offerings namely : Fire Suppression; Aerial Surveillance; and Maintenance, Repair and Overhaul (MRO). The company operates as a single operating segment. Its revenues are derived from aerial wildfire management, relief and suppression and the delivery of specialty aviation service. Geographically, it operates in Spain and United States.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).